IDH1 R132L

Clinical trials for IDH1 R132L explained in plain language.

Never miss a new study

Get alerted when new IDH1 R132L trials appear

Sign up with your email to follow new studies for IDH1 R132L, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Promising new combo therapy targets deadly childhood brain tumors

Disease control Recruiting now

This study tests whether adding the drug olutasidenib to standard chemotherapy can help children and young adults with a rare, aggressive brain cancer called IDH1-mutant high-grade glioma live longer. About 60 participants will receive the combination as maintenance therapy after…

Matched conditions: IDH1 R132L

Phase: PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control

Last updated Jun 15, 2026 19:03 UTC

IDH1 R132L

Get alerted when new IDH1 R132L trials appear

Promising new combo therapy targets deadly childhood brain tumors